AstraZeneca Strengthens China Hand With Massive R&D Boost
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca, which unlike many of its multinational peers continues to show strong growth in China, is building on this with a large investment aimed at building capacity for the development and manufacture of pharmaceuticals in the region.